Keros Therapeutics (NASDAQ:KROS) Coverage Initiated at Guggenheim

Guggenheim assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS) in a research report report published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $96.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. Oppenheimer began coverage on Keros Therapeutics in a research note on Tuesday, June 25th. They issued an outperform rating and a $102.00 price objective for the company. Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a buy rating on the stock in a research report on Thursday, September 12th. HC Wainwright reiterated a buy rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Finally, Truist Financial reiterated a buy rating and set a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $90.63.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $56.88 on Monday. The company has a fifty day moving average of $49.80 and a two-hundred day moving average of $52.79. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The stock has a market capitalization of $2.13 billion, a PE ratio of -11.04 and a beta of 1.22.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The company had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the prior year, the business earned ($1.27) earnings per share. Research analysts forecast that Keros Therapeutics will post -4.88 earnings per share for the current year.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the completion of the sale, the director now owns 119,522 shares of the company’s stock, valued at $5,260,163.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Keros Therapeutics by 7.9% during the first quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after purchasing an additional 113,563 shares during the last quarter. Darwin Global Management Ltd. boosted its position in Keros Therapeutics by 6.3% during the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after buying an additional 176,803 shares during the last quarter. Franklin Resources Inc. increased its stake in shares of Keros Therapeutics by 47.9% in the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after purchasing an additional 226,674 shares during the period. Finally, ADAR1 Capital Management LLC bought a new position in Keros Therapeutics in the 4th quarter worth approximately $27,367,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.